Compare Crispr Therapeutics AG (CRSP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Pfizer Inc — how do they compare? Crispr Therapeutics AG trades at $50.98 (market cap $4.88B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 32.7× Crispr Therapeutics AG's market cap, and Pfizer Inc pays a 6.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Pfizer Inc for 158 Days on average.
| CRSP | PFE | |
|---|---|---|
Market Cap | $4.88B | $159.59B |
Volume | 2,861,747 | 30,937,010 |
Sector | Health | Health |
52-Week High | $74.92 | $29.02 |
52-Week Low | $44.34 | $23.67 |
Typical Hold Time | 77 Days | 158 Days |
Enterprise Value | $3.30B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
